A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of JX11502MA Capsules in Patients With Schizophrenia
Latest Information Update: 12 Apr 2024
At a glance
- Drugs JX 11502MA (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Zhejiang Jingxin Pharmaceutical
Most Recent Events
- 12 Apr 2024 New trial record